Dr. Bassem I. Razzouk
Claim this profileAscension Saint Vincent Indianapolis Hospital
About Bassem I. Razzouk
Education:
Obtained MD from the American University of Beirut Faculty of Medicine, Lebanon, in 2006.
Completed Residency in Internal Medicine at St. Joseph Mercy Oakland, Michigan, USA (2007-2010).
Undertook Fellowship in Cardiovascular Disease at Saint Vincent Hospital, Worcester, Massachusetts, USA (2010-2013).
Experience:
Currently practices as a cardiologist at Saint Vincent Hospital and Health Care Center.
Area of expertise
Cancer
Bassem I. Razzouk has run 14 trials for Cancer. Some of their research focus areas include:
Neuroblastoma
Bassem I. Razzouk has run 8 trials for Neuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
Ascension Saint Vincent Indianapolis Hospital
Saint Vincent Hospital And Health Care Center
Clinical Trials Bassem I. Razzouk is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
More about Bassem I. Razzouk
Clinical Trial Related
8 years of experience running clinical trials · Led 32 trials as a Principal Investigator · 11 Active Clinical Trials
Treatments Bassem I. Razzouk has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Radiation Therapy
- Doxorubicin Hydrochloride
- Dexamethasone
Breakdown of trials Bassem I. Razzouk has run
Cancer
Neuroblastoma
Brain Tumor
Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bassem I. Razzouk specialize in?
Bassem I. Razzouk focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Bassem I. Razzouk currently recruiting for clinical trials?
Yes, Bassem I. Razzouk is currently recruiting for 11 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Bassem I. Razzouk has studied deeply?
Yes, Bassem I. Razzouk has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Bassem I. Razzouk?
Apply for one of the trials that Bassem I. Razzouk is conducting.
What is the office address of Bassem I. Razzouk?
The office of Bassem I. Razzouk is located at: Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana 46260 United States. This is the address for their practice at the Ascension Saint Vincent Indianapolis Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.